Drug Profile
N 121
Alternative Names: N-121Latest Information Update: 28 May 2021
Price :
$50
*
At a glance
- Originator Pharmeva
- Class Antineoplastics; Peptides
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 May 2021 No recent reports of development identified for preclinical development in Cancer in USA (Intratumoural)
- 01 Apr 2017 Preclinical trials in Cancer in USA (Intratumoural) before April 2017
- 01 Apr 2017 Pharmacodynamics and pharmacokinetics data from a preclinical study in Cancer presented at the 108th Annual Meeting of the American Association for Cancer Research (AACR-2017)